CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen.

abstract：:The human oral cavity represents a complex ecology of approximately 500 microbial species existing as commensals, and interacting with human/host factors. Perturbation of this ecosystem can lead to diseases of the oral cavity. The oral cavity also acts as a mirror of complex systemic diseases. Unique challenges and op...

journal_title：Pharmacogenomics

authors： Slavkin HC

更新日期：2003-03-01 00:00:00

abstract：:The 4th US FDA/Industry workshop, in a series on Pharmacogenomics, was on 'Biomarkers and Pharmacogenomics in Drug Development and Regulatory Decision Making' and was held on December 10-12, 2007 in Bethesda, MD, USA, with clear objectives to continue the dialogue that began in 2002 for enabling the use of biomarkers ...

journal_title：Pharmacogenomics

authors： Frueh FW,Salerno RA,Lesko LJ,Hockett RD

更新日期：2009-01-01 00:00:00

abstract：AIM:To investigate the pharmacokinetics of voriconazole when administered to HIV-positive patients receiving treatment with atazanavir-containing therapies according to CYP2C19 genotype. MATERIALS & METHODS:We describe four HIV-positive patients with pulmonary aspergillosis treated with voriconazole and atazanavir-bas...

journal_title：Pharmacogenomics

authors： Calcagno A,Baietto L,Pagani N,Simiele M,Audagnotto S,D'Avolio A,De Rosa FG,Di Perri G,Bonora S

更新日期：2014-07-01 00:00:00

abstract：AIM:To determine diagnostic accuracy of HLA-B*57:01 testing for prediction of abacavir-induced hypersensitivity and to quantify the clinical benefit of pretreatment screening through a meta-analytic review of published studies. METHODS:A comprehensive search was performed up to June 2013. The methodological quality of...

journal_title：Pharmacogenomics

authors： Cargnin S,Jommi C,Canonico PL,Genazzani AA,Terrazzino S

更新日期：2014-05-01 00:00:00

abstract：:The response to stress triggers transcriptional activation of genes involved in cell survival and/or cell death. Thus, the monitoring of gene expression levels in large gene sets or whole genomes in response to various agents (toxicogenomics) has been proposed as a tool for investigating mechanisms of toxicity. Althou...

journal_title：Pharmacogenomics

authors： Aubrecht J,Caba E

更新日期：2005-06-01 00:00:00

abstract：:Chronic obstructive pulmonary disease (COPD) is influenced by genetic and environmental factors. A large number of candidate gene-association studies and genome-wide linkage scans have been conducted to elucidate the genetic architecture underlying this disease. The compilation of these studies clearly revealed the co...

journal_title：Pharmacogenomics

authors： Bossé Y

更新日期：2009-04-01 00:00:00

abstract：:Atrial fibrillation (AF) is most common arrhythmia in general population, with increasing trend in mortality and morbidity. Electrophysiological and structural abnormalities, promoting abnormal impulse formation and propagation, lead to this disease. AF catheter ablation is related to a not small percentage of nonresp...

journal_title：Pharmacogenomics

authors： Sardu C,Santamaria M,Paolisso G,Marfella R

更新日期：2015-11-01 00:00:00

abstract：:Genetic variation in the beta 2-adrenoceptor and its associated proteins is common and therefore potentially relevant to the clinician. Several functional SNPs have been described but in vitro studies have yielded inconsistent results. Confounding due to the variable presence of other polymorphic alleles may be the ex...

journal_title：Pharmacogenomics

authors： Taylor DR,Kennedy MA

更新日期：2002-03-01 00:00:00

abstract：:High-throughput genotyping approaches are being developed to meet the demands of pharmacogenomnics, where numerous individuals are studied with thousands of single nucleotide polymorphism (SNP) markers. All non-gel-based genotyping approaches achieve allelic discrimination by one of four mechanisms: allele-specific hy...

journal_title：Pharmacogenomics

authors： Kwok PY

更新日期：2000-02-01 00:00:00

abstract：:Gastric cancer remains the second most frequent cause of cancer-related mortality. While surgery is traditionally the initial treatment for early-stage disease, the addition of chemotherapy has been shown to significantly increase overall survival and progression-free survival in advanced and metastatic stages of dise...

journal_title：Pharmacogenomics

authors： Patel JN,Fuchs CS,Owzar K,Chen Z,McLeod HL

更新日期：2013-07-01 00:00:00

abstract：AIMS:The current study investigates whether or not functional polymorphisms in the ATP-binding cassette transporter gene ABCG2 might affect gefitinib activity and/or toxicity in non-small-cell lung cancer (NSCLC) patients. MATERIALS & METHODS:Towards this end, ABCG2 polymorphisms and expression were assessed in DNA an...

journal_title：Pharmacogenomics

authors： Lemos C,Giovannetti E,Zucali PA,Assaraf YG,Scheffer GL,van der Straaten T,D'Incecco A,Falcone A,Guchelaar HJ,Danesi R,Santoro A,Giaccone G,Tibaldi C,Peters GJ

更新日期：2011-02-01 00:00:00

abstract：AIM:This study aimed to explore the role of miRNAs in rifampin-mediated induction of CYP3A4 in HepaRG cells. MATERIALS & METHODS:Microarray was performed to determine the expression of miRNAs in rifampin-treated HepaRG cells, followed by bioinformatics and luciferase reporter gene assay to analyze miRNAs that directly...

journal_title：Pharmacogenomics

authors： Yan L,Liu J,Zhao Y,Nie Y,Ma X,Kan Q,Zhang L

更新日期：2017-01-01 00:00:00

abstract：AIMS:Survivin (SVV) mRNA expression levels in peripheral blood of patients with gastrointestinal malignancies change significantly during the course of treatment. We wanted to scrutinize these findings in patients with esophageal carcinoma and furthermore evaluate whether the detection of mRNA and the change in detecti...

journal_title：Pharmacogenomics

authors： Hoffmann AC,Vallböhmer D,Grimminger P,Metzger R,Prenzel KL,Hoelscher AH,Brabender J

更新日期：2010-03-01 00:00:00

abstract：:The successful application of pharmacogenetics in routine clinical practice is still a long way from becoming a reality. In order to favor the transfer of pharmacogenetic results to clinical practice, especially in psychiatry, these studies must be optimized. This article reviews the strengths and weaknesses that char...

journal_title：Pharmacogenomics

authors： Mas S,Llerena A,Saíz J,Bernardo M,Lafuente A

更新日期：2012-11-01 00:00:00

abstract：:Recent studies have suggested an association between mutations in the IL-36RN gene and the onset of pustular generalized. In the literature, only one case of acute generalized exanthematous pustulosis (AGEP) induced by codeine in a patient with IL36RN mutation has been reported. Herein, we reported an unusual case of ...

journal_title：Pharmacogenomics

authors： Chadli Z,Ladhari C,Kerkeni E,Djobbi A,Fredj NB,Chaabane A,Boughattas NA,Aouam K

更新日期：2018-07-01 00:00:00

abstract：AIM:To determine the availability of pharmacogenetic and pharmacogenomic information for healthcare professionals in France during 2009 for anticancer drugs. MATERIALS & METHODS:We searched in the informatic version of the VIDAL dictionary which is currently used by healthcare professionals in France. We then compared...

journal_title：Pharmacogenomics

authors： Albertini L,Siest G,Jeannesson E,Visvikis-Siest S

更新日期：2011-05-01 00:00:00

abstract：:Evaluation of: Woynarowski JM, Krugliak M, Ginsburg H: Pharmacogenomic analyses of targeting the AT-rich malaria parasite genome with AT-specific alkylating drugs. Mol. Biochem. Parasitol. 154(1), 70-81 (2007) [1] . The sequencing of the malaria genome sought to expose the parasite's ability to cause disease and ident...

journal_title：Pharmacogenomics

authors： Yanow SK,Purcell LA,Lee M,Spithill TW

更新日期：2007-09-01 00:00:00

abstract：:Drug-induced liver injury (DILI) is an increasing health problem and a challenge for physicians, regulatory bodies and the pharmaceutical industry, not only because of its potential severity and elusive pathogenesis but also because it is often inaccurately diagnosed, commonly missed entirely and more often not report...

journal_title：Pharmacogenomics

authors： Andrade RJ,Robles M,Ulzurrun E,Lucena MI

更新日期：2009-09-01 00:00:00

abstract：:Cancers of the colon are commonly treated with fluoropyrimidines, which often cause severe toxicities in patients with certain variants in DPYD. Y186C (rs115232898) and a variant in the 3' untranslated region (rs12132152) are uncommon alleles previously observed in African-Americans. An African-American female underwe...

journal_title：Pharmacogenomics

authors： Sissung TM,Cordes L,Peer CJ,Gandhy S,Redman J,Strauss J,Figg WD

更新日期：2021-01-01 00:00:00

abstract：INTRODUCTION:Most cancer pharmacogenetic studies use germline DNA, as tumor tissue is often inaccessible in the advanced disease setting. However, this relies on the assumption that germline DNA is representative of the tumor genotype. To date, there has been little attention paid to defining the relationship between t...

journal_title：Pharmacogenomics

authors： Marsh S,Mallon MA,Goodfellow P,McLeod HL

更新日期：2005-12-01 00:00:00

abstract：:Vitamin K antagonists (coumarins) are widely-used oral anticoagulants for the prevention of venous thromboembolism and strokes. Wide inter-individual variation in dose response and frequent bleeds characterize the initiation of coumarin therapy. Over the past 10 years both genetic and nongenetic determinants of coumar...

journal_title：Pharmacogenomics

authors： Voora D,McLeod HL,Eby C,Gage BF

更新日期：2005-07-01 00:00:00

abstract：:In the growing field of genomics, the utility of returning certain research results to participants has become a highly debated issue. Existing guidelines are not explicit as to the kind of genomic information that should be returned to research participants. Moreover, very few current recommendations and articles in ...

journal_title：Pharmacogenomics

authors： Korol S,Hurlimann T,Godard B,de Denus S

更新日期：2013-04-01 00:00:00

abstract：AIM:We investigated 16 polymorphisms from three genes, dopamine receptor D2 (DRD2), catechol-O-methyl transferase (COMT) and brain derived neurotrophic factor (BDNF), which are involved in the dopaminergic pathways, and have been reported to be associated with susceptibility to schizophrenia and response to antipsychot...

journal_title：Pharmacogenomics

authors： Gupta M,Chauhan C,Bhatnagar P,Gupta S,Grover S,Singh PK,Purushottam M,Mukherjee O,Jain S,Brahmachari SK,Kukreti R

更新日期：2009-02-01 00:00:00

abstract：AIM:We conducted a genome-wide association study using the Illumina Exome Array to identify coding SNPs that may explain additional warfarin dose variability. PATIENTS & METHODS:Analysis was performed after adjustment for clinical variables and genetic factors known to influence warfarin dose among 1680 warfarin users...

journal_title：Pharmacogenomics

authors： Liu N,Irvin MR,Zhi D,Patki A,Beasley TM,Nickerson DA,Hill CE,Chen J,Kimmel SE,Limdi NA

更新日期：2017-07-01 00:00:00

abstract：AIM: HLA-B*15:02 screening should be performed to prevent antiepileptic drug induced severe cutaneous adverse reactions in populations of Asian origin. This study aimed to develop fast and reliable HLA-B*15:02 genotyping method and to investigate the distribution of HLA-B*15:02 in different Chinese ethnicities. MATERI...

journal_title：Pharmacogenomics

authors： Wang H,Kang X,Zhou S,Chen R,Liu Z,Han M,Chen C,Gong Y

更新日期：2017-06-01 00:00:00

abstract：:The most prescribed medication for controlling bronchoconstriction associated with asthma and chronic obstructive pulmonary disease are beta-agonists. The gene ADRbeta2 encodes the beta-2-adrenergic receptor and contains several common genetic variations that affect gene expression and receptor function in vitro. The ...

journal_title：Pharmacogenomics

authors： Hawkins GA,Weiss ST,Bleecker ER

更新日期：2008-03-01 00:00:00

abstract：:The recent introduction of new microarray expression technologies and the further development of established platforms ensure that the researcher is presented with a range of options for performing an experiment. Whilst this has opened up the possibilities for future applications, such as exon-specific arrays, increas...

journal_title：Pharmacogenomics

authors： Elvidge G

更新日期：2006-01-01 00:00:00

abstract：:Mother-to-child-transmission rates of HIV in the absence of any intervention range between 20 and 45%. However, the provision of antiretroviral drugs (ARVs) during pregnancy, delivery and breastfeeding can reduce HIV transmission to less than 2%. Physiological changes during pregnancy can influence ARV disposition. As...

journal_title：Pharmacogenomics

authors： Olagunju A,Owen A,Cressey TR

更新日期：2012-10-01 00:00:00

abstract：:Multiple sclerosis (MS) is a condition of the CNS marked by inflammation and neurodegeneration. Interferon (IFN)-beta was the first, and still is the main, immunomodulatory treatment for MS. Its clinical efficacy is limited, and a proportion of patients, ranging between 20-55%, do not respond to the therapy. Identific...

journal_title：Pharmacogenomics

authors： Vandenbroeck K,Urcelay E,Comabella M

更新日期：2010-08-01 00:00:00

abstract：:Randomized controlled trials are the gold standard for determining the efficacy of therapeutic interventions. However, medical practice has not evolved around the concept of randomized trials, but around the idea of careful observations, (anecdotal) case studies and the evaluation of retrospective data. Interventions ...

journal_title：Pharmacogenomics

authors： Frueh FW

更新日期：2009-07-01 00:00:00